Clinical utility of adjunctive retigabine in partial onset seizures in adults

Konrad Rejdak1
Jarogniew J Luszczki2,3
Barbara Błaszczyk4
Roman Chwedorowicz2
Stanislaw J Czuczwar2,5

1Department of Neurology, Medical University of Lublin, Lublin, 2Department of Pathophysiology, Medical University of Lublin, Lublin, 3Isobolography Analysis Laboratory, Institute of Agricultural Medicine, Lublin, 4Faculty of Health Sciences, High School of Economics and Law, Kielce, 5Department of Physiopathology, Institute of Agricultural Medicine, Lublin, Poland

Correspondence: Stanislaw J Czuczwar
Department of Pathophysiology, Medical University, Jacezkiewskiego 8, 20-090 Lublin, Poland Tel +48 81 718 73 65 Fax +48 81 718 73 64 Email czuczwarjs@yahoo.com

Abstract: In ~30% of epileptic patients, full seizure control is not possible, which is why the search for novel antiepileptic drugs continues. Retigabine exhibits a mechanism of action that is not shared by the available antiepileptic drugs. This antiepileptic enhances potassium currents via Kv7.2–7.3 channels, which very likely results from destabilization of a closed conformation or stabilization of the open conformation of the channels. Generally, the pharmacokinetics of retigabine are linear and the drug undergoes glucuronidation and acetylation. Results from clinical trials indicate that, in the form of an add-on therapy, retigabine proves an effective drug in refractory epileptic patients. The major adverse effects of the add-on treatment are dizziness, somnolence, and fatigue. This epileptic drug is also considered for other conditions – neuropathic pain, affective disorders, stroke, or even Alzheimer’s disease.

Keywords: antiepileptic drugs, epilepsy, seizure control

Introduction

Experimental data indicate that epileptic seizures may be associated with an imbalance between inhibitory (represented mainly by the γ-aminobutyric acid [GABA]-ergic system) and excitatory neurotransmission, mediated in general by glutamate in the central nervous system (CNS).1 The only exception appears to be absence seizures, probably resulting from an excess of GABA-ergic inhibition, causing 3 Hz oscillations in the thalamus.1 Still, the majority of epileptic seizures depend upon a reduced inhibition and excessive stimulation, and the existing antiepileptic drugs, including both classical and newer ones, through the targeting of the inhibitory or excitatory events restore the proper balance. Some of the drugs enhance GABA-mediated inhibition via a direct or indirect influence on GABA_A receptors. Direct GABA enhancers, modulating diverse binding sites on the GABA_A receptor complex, are benzodiazepines (diazepam, clonazepam), felbamate, phenobarbital, topiramate, and stiripentol.1–3 Other antiepileptics reduce the synaptic GABA uptake (tiagabine) or increase the synaptic GABA concentration through the inhibition of its catabolism (valproate or vigabatrin).1,2 Also, antiepileptic drugs may reduce glutamate-mediated excitation via a direct blockade of ionotropic glutamate receptors. For instance, phenobarbital or topiramate are α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor blockers,2 and recently, such an activity was ascribed to lamotrigine.4 On the other hand, felbamate has been documented to effectively block N-methyl-D-aspartate (NMDA) receptors through its potent affinity to the NR2B subunit.3 Certainly, some antiepileptic drugs can sufficiently reduce glutamate excitation indirectly.
For example, carbamazepine, lamotrigine, oxcarbazepine, and topiramate in the range of concentration of 150–1500 μM progressively inhibit veratridine-induced glutamate release from the hippocampal nerve endings, whilst carbamazepine, oxcarbazepine, and phenytoin (500–1500 μM) have been found effective against high potassium-induced glutamate release in the same experimental model. Felbamate has been documented to inhibit glutamate release in the rat entorhinal cortex, an effect very likely dependent on the blockade of presynaptic NMDA receptors. Many antiepileptic drugs control seizure activity through their blockade of voltage-operated sodium or calcium channels. Carbamazepine, lamotrigine, oxcarbazepine, phenytoin, topiramate, and valproate are effective sodium channel blockers. Ethosuximide and valproate reduce calcium currents via T-type channels, which is probably responsible for their anti-absence activity. L-type calcium channels are blocked by carbamazepine and topiramate; N-type channels, by levetiracetam; N- and P/Q-type, by gabapentin and pregabalin; N-, P-, and T-type channels, by zonisamide; and N-, P/Q-, R-, and T-channels, by lamotrigine.

Epilepsy as a serious neurological disorder affects circa 50 million people worldwide, which amounts to about 1% of the population. Seizures, whose frequency differs considerably between patients, distinctly deteriorate quality of life. Although antiepileptic drugs remain the main therapeutic option for the management of epilepsy, there are around 25%–30% of cases that do not fully respond to pharmacotherapy. From what was stated above, it is evident that both classical (carbamazepine, ethosuximide, phenytoin, phenobarbital, valproate) and newer (gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, or vigabatrin) antiepileptic drugs share similar mechanisms of action, affecting in comparable ways inhibitory and excitatory neurotransmissions or voltage-dependent ion channels. The main advantage of newer antiepileptics is that they exert milder adverse effects, their protective potential being of the same potency as that of classical antiepileptic drugs. The mechanism of action of only one newer antiepileptic drug, levetiracetam, is somewhat different from the battery of mechanisms listed above. Levetiracetam binds to the synaptic vesicle protein SV2A, which results in the modulation of neurotransmitter release.

A question arises whether antiepileptic drugs may take advantage of alternative mechanisms which can provide effective anticonvulsant activity along with the beneficial adverse profile. Retigabine (known as ezogabine in the United States), an antiepileptic drug sharing a completely different mechanism of action, is a good example of the search for completely novel antiepileptic drugs.

**Structure and metabolites of retigabine**

Chemically, retigabine is an N-(2-amino-4-(4-fluorobenzylamino)phenyl carbamic acid ethyl ester. The drug is subject to glucuronidation in humans and dogs, with the formation of two N-glucuronides: the N2- and the N4-glucuronide. The former metabolite prevails.

**Pharmacodynamics**

Retigabine, apart from its completely novel mechanism of action involving an enhancement of potassium currents, is also a GABA enhancer. Specifically, the drug has been proved to potentiate GABA-produced chloride currents in rat cortical neurons, and this very effect was evident for a relatively low concentration of retigabine, which amounted to 10 μmol. However, the involvement of benzodiazepine receptors in this effect is unlikely, because flumazenil did not block this particular action of retigabine. Nevertheless, both retigabine and GABA enhance their binding to the GABAA receptor complex and are capable of displacing a GABAA receptor tracer ligand, which may suggest retigabine interaction with the GABAA receptor at a place different from the benzodiazepine receptor. Apart from the receptor interactions, the synthesis of GABA has been elevated by retigabine in rat hippocampal slices.

As already mentioned above, retigabine is a modulator of potassium currents. Kv7 potassium channel (formerly known as KCNQ channel) is composed of five subunits, and apart from the Kv7.1, the remaining subunits (Kv7.2–7.5) are present in the nervous system. These four subunits conduct the low-threshold voltage-gated potassium current and form the “M-channel.” In most neurons, the M-channel is mainly composed of Kv7.2–7.3 subunits. Retigabine has been found as an effective potassium channel opener. The specificity of this effect is of great magnitude as this antiepileptic drug is still effective in this regard in low concentration as 0.1 μmol. The opening of the potassium channels by retigabine and the subsequent hyperpolarization in rat hippocampal-entorhinal slices is very likely to result from this specific effect. Further studies on the retigabine (0.1–10.0 μmol)-induced neuronal outward current have revealed that this drug considerably potentiates Kv7.2–7.3 currents, and this particular action is probably related to destabilization of a closed conformation or stabilization of the open conformation of the Kv7.2–7.3 channels. The Kv7.2–7.3 channel blocker, linopridine
(at 10 μmol) inhibits retigabine-induced outward potassium channels.22

The retigabine’s mechanism of action and that of some reference antiepileptic drugs is displayed in Table 1.

**Pharmacokinetics and metabolism**

In contrast to the majority of classical and some newer antiepileptic drugs, retigabine does not undergo any hepatic metabolism via cytochrome P-450 enzymes.23 Primarily, the drug is subject to glucuronidation to form N-glucuronide metabolites or to acetylation, which results in its conversion to mono-acetylated metabolite – AWD21-360.23,24 Human or dog metabolism of retigabine is mainly dependent on glucuronidation; whilst in rats, there are a couple of different metabolic pathways forming multiple metabolites of this antiepileptic drug.24 In humans and dogs, there is a constant ratio between unmetabolized retigabine and its N-glucuronide.14 The constant ratio may be indicative of a coupling between concentrations of retigabine and its metabolite through enterohepatic circulation and reactions of glucuronidation/deglucuronidation.14 In healthy volunteers on an oral daily dose of 600 mg of retigabine, evaluation of samples of plasma and urine have provided evidence on the existence of two metabolic pathways – glucuronidation and acetylation.23

Within the dose range of the first dose (100–350 mg and then twice daily for a fortnight), retigabine’s pharmacokinetics were linear and dose-dependent when evaluated in healthy white and black volunteers.25 After a single dose of 200 mg, a rapid absorption was noted, the mean maximum plasma concentration reaching 819 ng/mL within the mean time of 1.6 hours. In white volunteers, the mean apparent terminal half-life was 8 hours with the accompanying apparent clearance of 0.70 L × h⁻¹ × kg⁻¹; whilst in the black volunteers, the respective parameters were 25% and 30% lower.25

Similar results have been documented by Hermann et al,15 who after a single dose of the antiepileptic in young men aged 18–40 years, estimated the mean terminal half-life of 8.5 hours with the apparent clearance of 0.67 L × h⁻¹ × kg⁻¹. However, the mean maximum concentration was considerably lower (420 ng/mL), and the time to reach it was somewhat longer (2 hours).15

There are also data available on the effects of some other antiepileptic drugs on the pharmacokinetic parameters of retigabine in healthy volunteers. As regards to phenobarbital, this antiepileptic did not modify pharmacokinetics of retigabine, indicating that phenobarbital is likely to possess no influence on the retigabine’s metabolism.26 When combined with lamotrigine in healthy subjects, the retigabine’s clearance was reduced by 13%, and its mean half-life as well as area under the plasma concentration–time curve were increased by 7.5% and 15%, respectively.27 These authors present the view, that a competition between both drugs for renal excretion, but not for glucuronidation, might explain this interaction.27 They have also examined an impact of retigabine on the pharmacokinetics of lamotrigine, proving that lamotrigine’s metabolism is enhanced to a moderate degree – its apparent clearance being increased by 22%, and its mean half-life along with the area under the plasma concentration–time curve reduced by 15% and 18%, respectively. The authors of that study27 are of the opinion that this interaction is not likely to result from the inhibition by retigabine of metabolizing enzymes because this antiepileptic was without any significant influence upon the pharmacokinetics of carbamazepine, phenobarbital, phenytoin, topiramate, and valproate in epileptic patients.26,28

### Table 1 Mechanisms of action of RTG compared with those of other AEDs: VPA, LTG, TPM, OXC, CBZ, TGB, VGB, and GBP

<table>
<thead>
<tr>
<th>AEDs</th>
<th>Enhancement of GABA-mediated inhibition</th>
<th>Inhibition of glutamate excitation</th>
<th>Blockade of calcium channels</th>
<th>Blockade of sodium channels</th>
<th>Enhancement of potassium currents</th>
</tr>
</thead>
<tbody>
<tr>
<td>RTG</td>
<td>+</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>+</td>
</tr>
<tr>
<td>VPA</td>
<td>+/-</td>
<td>+</td>
<td>+ (T-type)</td>
<td>+/−</td>
<td>NE</td>
</tr>
<tr>
<td>LTG</td>
<td>NE</td>
<td>+</td>
<td>+ (N, P, Q, R, T)</td>
<td>+/−</td>
<td>NE</td>
</tr>
<tr>
<td>TPM</td>
<td>+</td>
<td>+</td>
<td>+ (L)</td>
<td>+/−</td>
<td>NE</td>
</tr>
<tr>
<td>OXC</td>
<td>NE</td>
<td>+</td>
<td>+ (N, P)</td>
<td>+/−</td>
<td>NE</td>
</tr>
<tr>
<td>CBZ</td>
<td>NE</td>
<td>+</td>
<td>+ (L)</td>
<td>+/−</td>
<td>NE</td>
</tr>
<tr>
<td>TGB</td>
<td>+</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>VGB</td>
<td>+</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>GBP</td>
<td>+</td>
<td>NE</td>
<td>+ (N, P)</td>
<td>NE</td>
<td>NE</td>
</tr>
</tbody>
</table>

**Notes:** +, well documented mechanism of action; NE, not effective at therapeutic AED concentrations; +/-, controversial results. Data are from Czuczwar and Patsalos.1 Czapinski et al,2 Siges et al,3 Siges et al,3 and Perucca.4

**Abbreviations:** AED, antiepileptic drug; CBZ, carbamazepine; GABA, γ-aminobutyric acid; GBP, gabapentin; LTG, lamotrigine; OXC, oxcarbazepine; RTG, retigabine; TGB, tiagabine; TPM, topiramate; VGB, vigabatrin; VPA, valproate.
Activity and toxicity in experimental models of epilepsy

Retigabine is effective in a variety of experimental models of epileptic seizures – the drug inhibits maximal electroshock-, pentylenetetrazol-, N-methyl-D-aspartate-, kainate-, picrotoxin-, and sound-induced seizure activity in rodents.\(^\text{13}\) Also, in doses producing no or mild adverse effects, retigabine is effective in elevating the after-discharge threshold and reducing the after-discharge duration in fully hippocampal-kindled rats.\(^\text{29}\) Remarkably, retigabine in three age groups of young rats (P14, P21, and P35) was capable of inhibiting the evolution of kindling to the maximum stage, and in one group (P14), it distinctly delayed the acquisition of focal convulsions. These data may lead to a conclusion that apart from the apparent anticonvulsant activity, retigabine possesses an antiepileptogenic potential as well.\(^\text{29}\) It is remarkable that the developmental profile of another potent antiepileptic drug, topiramate, was quite distinct in that this drug, in contrast to retigabine, was least effective in P14 rats.\(^\text{30}\) Nevertheless, retigabine was much weaker as an anticonvulsant in mutant Sz1 mice that were deprived of most of the C-terminus in their Kv7.2 channels, whilst its potent anticonvulsant activity against partial psychomotor seizures of the C-terminus in their Kv7.2 channels, whilst its potent anticonvulsant activity against partial psychomotor seizures was not affected in the littermate control.\(^\text{31}\)

Retigabine does not exert any harmful activity upon reproductive functions in rats, and no teratogenic potential of this antiepileptic has been found in rats or rabbits.\(^\text{32}\) Perinatal or postnatal treatment with retigabine is not associated with any developmental toxicity, the only exception being the animals injected with the highest dose of this antiepileptic drug, whose growth is significantly reduced.\(^\text{32}\)

Acute toxicity evaluations have revealed that in different animal species, retigabine induces a number of toxic effects, mainly derived from the CNS – hypo- or hyperkinesia, uncoordinated movements, tremor, stilted gait, and convulsions. However, electroencephalographic parameters were not affected by retigabine in isolated guinea-pig heart or in vivo in dogs (orally up to 38 mg/kg for a week).\(^\text{32}\)

Interactions of retigabine with classical and newer antiepileptic drugs in mice

Combinations of retigabine with classical or newer antiepileptic drugs have been evaluated experimentally with the use of two methods. One method assumed the combined treatment of retigabine at subprotective doses with active doses of other antiepileptics. Based on this experimental approach, De Sarro et al\(^\text{33}\) have found that retigabine at 0.5 mg/kg potentiated the anticonvulsant activity of carbamazepine, diazepam, felbamate, lamotrigine, phenytoin, phenobarbital, and valproate against sound-induced convulsions in DBA/2 mice. The most distinct reductions in the respective ED\(_{50}\) values were observed for diazepam, phenobarbital, phenytoin, and valproate. The protective indices for the combined treatments were better than that for retigabine alone. The observed interactions may be interpreted in terms of pharmacodynamic mechanisms, because in no case did retigabine change the total or free plasma concentrations of the studied antiepileptic drugs.\(^\text{33}\)

With a method of isobolographic analysis, one can accurately evaluate the final effects of a drug combination as synergistic, additive, or antagonistic.\(^\text{34}\) In the test of maximal electroshock in mice, the dose-effect curves for retigabine and valproate were parallel, so it was possible to assess their interaction in fixed-dose ratios other than just 1:1. It is noteworthy that in three dose ratios of 1:3, 1:1, and 3:1, the combination of retigabine + valproate proved synergistic against maximal electroshock in mice. However, the dose effects curves for retigabine and carbamazepine or lamotrigine were not parallel, and consequently, only one fixed-dose ratio of 1:1 of these drugs could be evaluated. In both cases (retigabine + carbamazepine or retigabine + lamotrigine) additivity was noted against maximal electroshock-induced convulsions in mice. Neurotoxic evaluation has indicated that no evaluated combination was associated with disturbed motor coordination, long-term memory, or muscular strength. Determinations of the concentrations of all drugs in a given combined treatment have revealed that only in the fixed dose ratio of 3:1 (retigabine:valproate) combination, the free plasma and total brain levels of valproate were elevated.\(^\text{34}\)

Clinical efficacy, safety, and tolerability

Initial clinical evidence indicated that retigabine both as mono- or polytherapy in 15 healthy volunteers was in principle well tolerated. Headache was most frequently reported, and there were no laboratory test or ECG disturbances. The drug had to be withdrawn in one epileptic patient due to severe abdominal pain.\(^\text{26}\)

Retigabine was subsequently studied as an add-on drug in patients with partial onset seizures within a Phase II multicenter, randomized, placebo-controlled clinical trial, being titrated to daily doses of 600, 900, and 1200 mg over a period of 2–6 weeks.\(^\text{35}\) The respective responder rates for these doses were 23%, 32%, and 33% versus 16% for placebo,
which reached the level of significance except for the dose of 600 mg. The most frequently reported adverse effects were somnolence, dizziness, confusion, speech disorder, vertigo, tremor, amnesia, abnormal thinking, abnormal gait, paresthesia, and diplopia.35

Finally, the drug was tested in two Phase III multicenter, randomized, double-blind studies in which retigabine was added to 1–3 antiepileptic drugs,36 and the results of these trials led to formal registration of the drug by the European Medicines Agency and the Food and Drug Administration. The first study, sponsored by Valeant36 and registered as RESTORE 1 assumed titration of this antiepileptic to 1200 mg. There were two periods of observation: an 8-week, prospective baseline phase and an 18-week double-blind treatment period (with 6-week initial dose titration phase). Two primary endpoints were considered: percentage change in 28-day total partial seizure frequency between baseline and double-blind period, and responder rate, defined as 50% reduction in 28-day total partial seizure frequency between baseline and maintenance phase. A total of 306 patients were randomized, and 305 of those were used in the intention-to-treat analysis. The retigabine treatment group had 44.3% reduction in monthly seizure frequency compared with 17.5% in the placebo group ($P = 0.001$). Responder rate was 44.4% in the treated group, while 17.8% in the placebo group ($P = 0.001$). During the maintenance phase, 5% of patients in the treated group were seizure-free compared with 1% in the placebo group, but the difference did not reach statistical significance. However, the percentage of seizure-free days in the treated group was significantly greater than in the placebo group. The proportion of patients discontinuing due to treatment-emergent adverse events (TEAEs) was 26.8% (retigabine) versus 8.6% (placebo). Dizziness, somnolence, fatigue, confusion, dysarthria, urinary tract infection, ataxia, and blurred vision were the most common TEAEs reported by more patients treated with retigabine than placebo.36 The second study, known as RESTORE 2, was also sponsored by Valeant.37 The study was designed with four phases: a prospective 8-week baseline, 4-week titration up to 600 mg/day or 900 mg/day, 12-week maintenance, and a 4-week transition phase if patients elected to participate in the open-label extension phase. A total of 539 patients were randomized, and 538 patients were included in the intention-to-treat analysis. The median percentage reduction was greater for both the 600 mg/day (27.9%, $P = 0.007$) and 900 mg/day (39.9%, $P = 0.001$) treatment groups compared with placebo (15.9%). Responder rate defined as 50% reduction in seizure frequency was significantly higher in both the 600 mg/day (38.6%) and the 900 mg/day (47.0%) group than in placebo-treated patients (18.9%, $P = 0.001$). Treatment discontinuations due to adverse events (AEs) were more likely with retigabine than with placebo (placebo, 8%; 600 mg, 17%; 900 mg, 26%). The most commonly reported (>10%) AEs in the placebo, retigabine 600 mg/day and 900 mg/day groups were dose dependent and included dizziness (7%, 17%, 26%, respectively), somnolence (10%, 14%, 26%), headache (15%, 11%, 17%), and fatigue (3%, 15%, 17%).37

Except CNS-related effects, there is another issue which deserves special attention. There was some experimental evidence that retigabine had adverse effects on bladder function in a rat model. Investigators from RESTORE 1 and 2 studies performed detailed evaluation of all possible adverse reactions from urinary tract in retigabine-treated patients. In RESTORE 2, three patients on retigabine reported chromaturia, and three patients complained of adverse events of the urinary tract (one nephritis and two urinary retention). The RESTORE 1 study revealed that 15 of the retigabine-treated patients had increased post-void residual volumes compared with six of the placebo-treated patients. Among other AEs reported were urinary tract infection, urinary hesitation, dysuria, and chromaturia. In general, the safety profile in both studies was good and no serious adverse effects were reported.

RESTORE 1 and 2 were actually randomized controlled short-term studies, and there are no results available as yet on long-term efficacy and safety of retigabine in epileptic patients.

Looking to the future, there are several clinical issues to be studied with regard to retigabine treatment in epilepsy patients. It would be very important to assess the clinical spectrum for different seizure types, especially absence, tonic-clonic, as well as myoclonic generalized seizures both in pediatric or adult populations, especially when used in newly diagnosed epilepsy. In addition, studies on the efficacy of retigabine in pediatric patients with partial-onset seizures or Lennox-Gastaut syndrome have been planned.32 There is experimental evidence that retigabine has broad anticonvulsant activity when used in various models of generalized seizures.38 Similarly, the efficacy and safety of the drug should be studied in special populations like elderly patients, women in child-bearing age, and patients with intellectual disability. Particular attention should be put on co-morbidities including diseases of the urinary tract, having in mind the known effects of the drug on urinary retention. Above aspects will definitely be taken up in future post-marketing studies to provide more data on possible applications of the drug in wide clinical practice.
Nonepilepsy potential of retigabine

Antiepileptic drugs have been shown effective in conditions other than epilepsy, and their clinical use in neuropathic pain, migraine, affective disorders, spasticity, or restless legs syndrome has been approved.39 There are experimental data indicating that retigabine inhibits neuropathic pain in models of chronic constriction injury and spared nerve or in the formalin test.40,41 The drug is also likely to exert some antimanic activity as it distinctly counteracts enhanced locomotor activity by amphetamine + chloridazepoxide in rats.42 Retigabine has also been proved to attenuate the psychostimulatory effects of cocaine, methylphenidate, or phencyclidine and thus may be considered as an anti-addictive drug.43 Other basic studies have provided evidence that retigabine actually exerts anxiolytic and antidystonic effects.44,45 Some case reports and even a clinical trial indicate that retigabine may delay the progression of Alzheimer’s disease.46,47 Possible nonepilepsy uses of retigabine are listed and compared with those of other antiepileptic drugs in Table 2.

Final considerations

Although many newer antiepileptic drugs have been available in the last two decades, the percentage of drug-resistant patients has not significantly improved.1,2,12 One possible reason for this apparent failure may be that newer antiepileptic drugs are usually added to the existing antiepileptic treatment in drug-resistant patients. Thus, such a therapeutic approach is independent of the existing treatment, and the antiepileptic drugs are combined randomly. Considering experimental data on the combined treatment, it is evident that the final outcome of a drug interaction may be synergy, additivity, or antagonism.48 It would be thus reasonable to consider drug combinations exerting anticonvulsant synergy from both experimental48 and clinical points of view.49 In this context, best therapeutic results with retigabine as an add-on drug, would be expected in its combination with valproate, which is purely synergistic.34 Combinations of carbamazepine + retigabine or lamotrigine + retigabine might be less clinically effective.34

The adverse profile of retigabine is in fact the result of its interactions with the existing antiepileptic treatment. So far, there are no data available on the tolerability of retigabine applied in the form of monotherapy.

Some reports indicate that retigabine may exert neuroprotective effects in some brain areas (e.g., pyriform cortex) in vivo after kainate-induced status epilepticus in rats.50 Also, there are data on its neuroprotective action in vitro.51 However, the significance of these findings in terms of epileptogenesis may be unclear since there is no distinct link between these two events.50

The research on positive potassium channel modulators is growing very fast. There is currently a compound available, which contrary to retigabine, may activate the mutated Kv7.2 channel. This finding can actually broaden the practical utility of potassium channel activators.32

To date, there are several reviews devoted to retigabine (the last four being published in 2011).53–61 Whilst dealing with generally similar points (pharmacokinetics and pharmacodynamics of retigabine along with its clinical efficacy and adverse effects), this review is also focused on the effectiveness of retigabine in combinations with other antiepileptic drugs as well on its nonepilepsy potential, which is also mentioned by Weisenberg and Wong.59

Conclusion

Retigabine is the first antiepileptic drug able to enhance neuronal potassium currents, and this effect is blocked by the Kv7.2–7.3 channel blocker linopride.22 This antiepileptic has shown a good experimental profile in interactions with valproate (anticonvulsant synergy) or carbamazepine and lamotrigine (anticonvulsant additivity).34

Clinically, in patients with refractory epilepsy, retigabine in the form of an add-on therapy, led to considerable improvement, reflected by a significant reduction in seizure

Table 2 Nonepilepsy uses of RTG and other AEDs: CBZ, GBP, LTG, OXC, and TPM

<table>
<thead>
<tr>
<th>AEDs*</th>
<th>Nonepilepsy indications</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Neuropathic pain</td>
<td>Bipolar disorder</td>
<td>Dystonia</td>
<td>Cocaine addiction</td>
</tr>
<tr>
<td>RTG</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+/−</td>
</tr>
<tr>
<td>CBZ</td>
<td>+/−</td>
<td>+</td>
<td>+/−</td>
<td>+/−</td>
<td>+/−</td>
</tr>
<tr>
<td>GBP</td>
<td>+</td>
<td>+/−</td>
<td>−/−</td>
<td>+/−</td>
<td>+/−</td>
</tr>
<tr>
<td>LTG</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+/−</td>
<td>+/−</td>
</tr>
<tr>
<td>OXC</td>
<td>+</td>
<td>+/−</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>TPM</td>
<td>+/−</td>
<td>+/−</td>
<td>+/−</td>
<td>+/−</td>
<td>+/−</td>
</tr>
</tbody>
</table>

Notes: +, drug effective; +/−, controversial data; −, drug ineffective; *experimental data; †initial clinical data; ‘dystonia as a result of drug toxicity; ‡limited number of patients.

*All data are from references,16–19 except for RTG, which are from references.40–43,45–47

Abbreviations: AED, antiepileptic drug; CBZ, carbamazepine; GBP, gabapentin; LTG, lamotrigine; OXC, oxcarbazepine; RTG, retigabine; TPM, topiramate.
frequency with an accompanying good tolerability profile. There are also data showing that the clinical use of retigabine may be considered also for nonepilepsy indications (e.g., neuropathic pain, mania, possibly bipolar disorder, stroke, and Alzheimer’s disease).

**Disclosure**
K Rejdak and SJ Czuczwar have lectured for GlaxoSmithKline. SJ Czuczwar and JJ Luszczki published a paper with JZ Wu, as co-author, from Valeant Pharmaceuticals International. Other authors report no conflicts of interest in this work.

**References**